SPAG6 and ductal breast carcinoma in situ: Using these discriminative CpGs on basis of FC, SPAG6 showed a significant higher methylation level in breast cancer (mean of 6.84% in benign controls versus 8.79% in breast cancer, p = 0.0073), DCIS (6.84% versus 8.79%, p = 0.0258) and early invasive breast cancer (6.84% versus 8.80%, p = 0.0168, Figure 2A).